S&P 500

5.460,48

-0,41%

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Mineralys Therapeutics Inc (MLYS)
Mineralys Therapeutics Inc (MLYS) Notícias

MLYS

Mineralys Therapeutics (MLYS)

Mineralys Therapeutics Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:MLYS

1 2 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
17/06/2024	17:33	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MLYS	Mineralys Therapeutics Inc
17/06/2024	17:31	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:MLYS	Mineralys Therapeutics Inc
14/06/2024	09:06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MLYS	Mineralys Therapeutics Inc
14/06/2024	09:00	GlobeNewswire Inc.	Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors	NASDAQ:MLYS	Mineralys Therapeutics Inc
09/05/2024	08:10	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:MLYS	Mineralys Therapeutics Inc
09/05/2024	08:00	GlobeNewswire Inc.	Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update	NASDAQ:MLYS	Mineralys Therapeutics Inc
06/05/2024	09:00	GlobeNewswire Inc.	Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference	NASDAQ:MLYS	Mineralys Therapeutics Inc
02/05/2024	09:00	GlobeNewswire Inc.	Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024	NASDAQ:MLYS	Mineralys Therapeutics Inc
21/03/2024	08:00	GlobeNewswire Inc.	Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	NASDAQ:MLYS	Mineralys Therapeutics Inc
13/03/2024	17:05	GlobeNewswire Inc.	Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024	NASDAQ:MLYS	Mineralys Therapeutics Inc
15/02/2024	18:20	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:MLYS	Mineralys Therapeutics Inc
08/02/2024	10:00	GlobeNewswire Inc.	Mineralys Therapeutics Announces $120 Million Private Placement Financing	NASDAQ:MLYS	Mineralys Therapeutics Inc
29/01/2024	18:05	GlobeNewswire Inc.	Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference	NASDAQ:MLYS	Mineralys Therapeutics Inc
04/01/2024	18:05	GlobeNewswire Inc.	Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer	NASDAQ:MLYS	Mineralys Therapeutics Inc
21/12/2023	18:05	GlobeNewswire Inc.	Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension	NASDAQ:MLYS	Mineralys Therapeutics Inc
11/11/2023	13:30	GlobeNewswire Inc.	Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023	NASDAQ:MLYS	Mineralys Therapeutics Inc
09/11/2023	18:05	GlobeNewswire Inc.	Mineralys Therapeutics to Participate in Three Upcoming Conferences	NASDAQ:MLYS	Mineralys Therapeutics Inc
07/11/2023	18:05	GlobeNewswire Inc.	Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update	NASDAQ:MLYS	Mineralys Therapeutics Inc
02/11/2023	11:00	GlobeNewswire Inc.	Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting	NASDAQ:MLYS	Mineralys Therapeutics Inc
31/10/2023	17:05	GlobeNewswire Inc.	Mineralys Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on Tuesday, November 7, 2023	NASDAQ:MLYS	Mineralys Therapeutics Inc
13/10/2023	17:10	GlobeNewswire Inc.	Mineralys Therapeutics Announces Upcoming Poster Presentations at Two Scientific Conferences in November 2023	NASDAQ:MLYS	Mineralys Therapeutics Inc
19/09/2023	17:00	GlobeNewswire Inc.	Praxis Bioresearch Expands its Board of Directors with Appointment of Adam Levy	NASDAQ:MLYS	Mineralys Therapeutics Inc
14/09/2023	17:05	GlobeNewswire Inc.	Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne Karydas	NASDAQ:MLYS	Mineralys Therapeutics Inc
11/09/2023	17:05	GlobeNewswire Inc.	Mineralys Therapeutics to Participate in the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023	NASDAQ:MLYS	Mineralys Therapeutics Inc
10/09/2023	08:47	GlobeNewswire Inc.	Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension	NASDAQ:MLYS	Mineralys Therapeutics Inc
10/09/2023	08:45	GlobeNewswire Inc.	Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions	NASDAQ:MLYS	Mineralys Therapeutics Inc
05/09/2023	17:05	GlobeNewswire Inc.	Mineralys Therapeutics Selected for Oral Poster Presentation of Target-HTN Phase 2 Trial Results at 2023 AHA Hypertension Scientific Sessions	NASDAQ:MLYS	Mineralys Therapeutics Inc
29/08/2023	17:05	GlobeNewswire Inc.	Mineralys Therapeutics to Participate in the Wells Fargo Securities Healthcare Conference on Thursday, September 7, 2023	NASDAQ:MLYS	Mineralys Therapeutics Inc
07/08/2023	17:05	GlobeNewswire Inc.	Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update	NASDAQ:MLYS	Mineralys Therapeutics Inc
31/07/2023	17:05	GlobeNewswire Inc.	Mineralys Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on Monday, August 7, 2023	NASDAQ:MLYS	Mineralys Therapeutics Inc